RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5

Kinome-wide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid-restricted kinase, GRK6

(2009) R. E. Tiedemann et al.   BLOOD

Identification of Copy Number Abnormalities and Inactivating Mutations in Two Negative Regulators of Nuclear Factor- B Signaling Pathways in Waldenstrom's Macroglobulinemia

(2009) E. Braggio et al.   CANCER RESEARCH

Bortezomib

(2009) Monique P. Curran et al.   DRUGS

Different mutants of PSMB5 confer varying bortezomib resistance in T lymphoblastic lymphoma/leukemia cells derived from the Jurkat cell line

(2009) Shuqing Lü et al.   EXPERIMENTAL HEMATOLOGY

Pharmacogenomic approach for the identification of novel determinants of acquired resistance to oxaliplatin in colorectal cancer

(2009) A. Martinez-Cardus et al.   MOLECULAR CANCER THERAPEUTICS

Roscovitine increases intracellular calcium release and capacitative calcium entry in PC12 cells

(2009) Ho Sook Choi et al.   NEUROSCIENCE LETTERS

Molecular basis of bortezomib resistance: proteasome subunit  5 (PSMB5) gene mutation and overexpression of PSMB5 protein

(2008) R. Oerlemans et al.   BLOOD

NF-??B in the pathogenesis and treatment of multiple myeloma

(2008) Zhi-Wei Li et al.   CURRENT OPINION IN HEMATOLOGY

A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor

(2008) Nicholas C Turner et al.   EMBO JOURNAL

Overexpression of the PSMB5 gene contributes to bortezomib resistance in T-lymphoblastic lymphoma/leukemia cells derived from Jurkat line

(2008) Shuqing Lü et al.   EXPERIMENTAL HEMATOLOGY

Cdk5-mediated regulation of the PIKE-A-Akt pathway and glioblastoma cell invasion

(2008) R. Liu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA